Ventyx Biosciences Inc
VTYX2.300USD
-0.090-3.77%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
163.84MMarket Cap
LossP/E TTM
More Details of Ventyx Biosciences Inc Company
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Company Info
Ticker SymbolVTYX
Company nameVentyx Biosciences Inc
IPO dateOct 21, 2021
CEOMr. Raju Mohan, Ph.D.
Number of employees79
Security typeOrdinary Share
Fiscal year-endOct 21
Address12790 El Camino Real, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92130
Phone18589452393
Websitehttps://ventyxbio.com/
Ticker SymbolVTYX
IPO dateOct 21, 2021
CEOMr. Raju Mohan, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Roy M. Gonzales
Mr. Roy M. Gonzales
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William R. White, J.D.
Mr. William R. White, J.D.
Independent Director
Independent Director
--
--
Ms. Onaiza Cadoret - Manier
Ms. Onaiza Cadoret - Manier
Independent Director
Independent Director
--
--
Mr. Matthew (Matt) Moore
Mr. Matthew (Matt) Moore
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Raju Mohan, Ph.D.
Mr. Raju Mohan, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.30M
--
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Executive Chairperson of the Board
Executive Chairperson of the Board
130.00K
--
Dr. John M. Nuss, Ph.D.
Dr. John M. Nuss, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Somasundaram Subramaniam
Mr. Somasundaram Subramaniam
Independent Director
Independent Director
--
--
Dr. Allison J. Hulme, Ph.D.
Dr. Allison J. Hulme, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Forman, M.D., Ph.D.
Dr. Mark Forman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.27%
Affinity Asset Advisors LLC
6.36%
New Science Ventures, LLC
5.65%
The Vanguard Group, Inc.
4.43%
Tang Capital Management, LLC
4.35%
Other
70.94%
Shareholders
Shareholders
Proportion
Point72 Asset Management, L.P.
8.27%
Affinity Asset Advisors LLC
6.36%
New Science Ventures, LLC
5.65%
The Vanguard Group, Inc.
4.43%
Tang Capital Management, LLC
4.35%
Other
70.94%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.20%
Investment Advisor/Hedge Fund
15.82%
Investment Advisor
13.55%
Venture Capital
5.88%
Individual Investor
4.11%
Research Firm
4.08%
Family Office
0.27%
Other
27.08%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
368
54.53M
76.62%
-50.77M
2025Q1
385
51.70M
72.65%
-54.51M
2024Q4
397
65.14M
91.63%
-35.16M
2024Q3
387
62.43M
88.32%
-37.01M
2024Q2
376
67.39M
95.54%
-30.30M
2024Q1
369
70.49M
100.19%
-8.56M
2023Q4
345
54.61M
92.50%
-19.94M
2023Q3
315
66.31M
112.60%
-5.18M
2023Q2
302
65.66M
112.13%
-3.35M
2023Q1
267
64.47M
110.86%
+4.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Point72 Asset Management, L.P.
4.23M
5.95%
+2.45M
+137.64%
Mar 31, 2025
Affinity Asset Advisors LLC
4.06M
5.7%
+4.06M
--
May 22, 2025
New Science Ventures, LLC
4.03M
5.67%
-3.07M
-43.23%
Mar 28, 2025
The Vanguard Group, Inc.
3.51M
4.94%
+5.11K
+0.15%
Mar 31, 2025
Tang Capital Management, LLC
3.10M
4.36%
--
--
Mar 31, 2025
Mohan (Raju)
2.30M
3.24%
--
--
Apr 10, 2025
Vestal Point Capital, LP
2.00M
2.81%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.39M
1.96%
-3.09M
-68.91%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
